Poster
82 |
Investigating RNA binding proteins and their modifiers as potential drug targets in Leishmania and T. cruzi |
Leishmaniasis and Chagas disease are global infectious diseases for which treatments are challenged and vaccines are not available. The causative agents are digenetic and obligate intracellular protozoan trypanosomatids, that present a peculiar gene expression regulation, occurring preferentially at the post transcriptional level, mediated by trans-regulator elements such as ribonucleoprotein complexes (mRNPs). Our objective is to molecularly verify and characterize RNA Binding Proteins (RBPs) as essential regulators for parasite survival and pathology. 8 amastigote-specific mRNA-bound RBPs were selected that display known RNA-binding domains (Pablos, Ferreira et al., 2019). Knockout lines were generated in L. mexicana for 3 of these and preliminary promastigote growth analysis revealed a decreased replication rate. Another 3 RBPs are likely essential even to promastigote stages as CRISPR-cas9 assisted knockout has failed repeatedly. For these candidates, a low-cost inducible depletion strategy is being optimized to analyse RBPs essential to all stages. These findings suggest at least 6 relevant targets that contribute to parasite fitness for further investigation, with focus on evaluating the impact upon amastigote stage viability and virulence. Building upon this, 6 RBPs have been tagged for immunoprecipitations to identify RNA targets; providing insight into vulnerable functional pathways. We hope to extend this investigation into orthologous essential RBPs in T. cruzi amastigotes; examining conserved RBP function and the potential for common combative strategies.
Key words: Trypanosomatids, Leishmania, Trypanosoma cruzi, RBP, RNA, Drug Targets.